Literature DB >> 11867029

Acute coronary syndrome is a common clinical presentation of in-stent restenosis.

Darren L Walters1, Scott A Harding, Craig R Walsh, Phillip Wong, Eugene Pomerantsev, Ik Kyung Jang.   

Abstract

Coronary stents have been the major advancement in percutaneous coronary intervention in the last decade and are used in 60% to 80% of patients. However, in-stent restenosis continues to be a problem, occurring in 20% to 30% of cases. The clinical presentation of patients who develop restenosis after stenting has not been well characterized. In this study we compared the clinical presentation of in-stent restenosis with that of restenosis without stenting. Of 739 patients who underwent percutaneous coronary intervention and had repeat catheterization between October 1, 1997, and June 30, 2000, 262 consecutive patients with recurrent ischemia and restenosis were identified: 191 patients with (group A) and 71 without (Group B) stenting. Patients who underwent interventions in bypass grafts and those who developed early acute stent thrombosis were excluded from the study. Recurrent clinical ischemia occurred at a mean of 5.5 months in group A and 6.5 months in group B (p = 0.24). Rest angina (Braunwald class II and III) was more frequent in group A (48% vs 32%, p = 0.032). Acute coronary syndromes, the combination of rest angina, and acute myocardial infarction were also more frequent in group A (68% vs 46%, p = 0.03). Patients in group A were more likely to have angiographically visible thrombus than those in group B (9% vs 0%, p = 0.02). Thus, acute coronary syndromes are a common clinical presentation of restenosis among patients whose follow-up angiogram is obtained for clinical reasons, and occur more frequently in patients with in-stent restenosis than in those with restenosis without stenting.

Entities:  

Mesh:

Year:  2002        PMID: 11867029     DOI: 10.1016/s0002-9149(01)02285-8

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Characterizing the spectrum of in-stent restenosis: implications for contemporary treatment.

Authors:  Gordon E Pate; May Lee; Karin Humphries; Eric Cohen; Robert Lowe; Rebecca S Fox; Robert Teskey; Christopher E Buller
Journal:  Can J Cardiol       Date:  2006-12       Impact factor: 5.223

Review 2.  Causes, assessment, and treatment of stent thrombosis--intravascular imaging insights.

Authors:  Daniel S Ong; Ik-Kyung Jang
Journal:  Nat Rev Cardiol       Date:  2015-03-17       Impact factor: 32.419

3.  Assessment of in-stent restenosis using 64-MDCT: analysis of the CORE-64 Multicenter International Trial.

Authors:  Joanna J Wykrzykowska; Armin Arbab-Zadeh; Gustavo Godoy; Julie M Miller; Shezhang Lin; Andrea Vavere; Narinder Paul; Hiroyuki Niinuma; John Hoe; Jeffrey Brinker; Faisal Khosa; Sheryar Sarwar; Joao Lima; Melvin E Clouse
Journal:  AJR Am J Roentgenol       Date:  2010-01       Impact factor: 3.959

4.  Intravascular magnetic resonance/radiofrequency may enhance gene therapy for prevention of in-stent neointimal hyperplasia.

Authors:  Fabao Gao; Bensheng Qiu; Sourav Kar; Xiangcan Zhan; Lawrence V Hofmann; Xiaoming Yang
Journal:  Acad Radiol       Date:  2006-04       Impact factor: 3.173

Review 5.  Diabetes and restenosis.

Authors:  Scott Wilson; Pasquale Mone; Urna Kansakar; Stanislovas S Jankauskas; Kwame Donkor; Ayobami Adebayo; Fahimeh Varzideh; Michael Eacobacci; Jessica Gambardella; Angela Lombardi; Gaetano Santulli
Journal:  Cardiovasc Diabetol       Date:  2022-02-14       Impact factor: 9.951

6.  Clinical outcomes in patients treated for coronary in-stent restenosis with drug-eluting balloons: Impact of high platelet reactivity.

Authors:  Adrienn Tornyos; Dániel Aradi; Iván G Horváth; Attila Kónyi; Balázs Magyari; Tünde Pintér; András Vorobcsuk; Dániel Tornyos; András Komócsi
Journal:  PLoS One       Date:  2017-12-07       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.